The GPC2 CAR T cell therapy represents a novel approach in treating relapsed or refractory neuroblastoma and metastatic retinoblastoma, conditions with limited treatment options and poor prognoses. The market for pediatric oncology therapies is growing, driven by increasing incidences of childhood cancers and advancements in immunotherapy. The collaboration with notable institutions such as Gilead Sciences and the National Cancer Institute enhances credibility and potential for successful commercialization. However, the competitive landscape includes other CAR T therapies and emerging immunotherapies targeting similar malignancies, necessitating a robust differentiation strategy and clear demonstration of clinical efficacy and safety.